Study of blood platinum concentration transition in TACE using the cisplatin containing Hepasufhia

Study of blood platinum concentration transition in TACE using the cisplatin containing Hepasufhia - CDDP-Hepasphia pharmacokinetics study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017508

Enrollment

Registered

2015-05-12

Start date

2015-05-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

DEB-TACE using the cisplatin (50mg)containing Hepasufhia (50-100 micro m).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 No indication for surgical resection. 2 Histologically or clinically cobfirmed hepatocellular carcinoma. 3 Ages 30 to 80 years old. 4 Life expectancy is more than 3months 5 Written informed consent was obtained. 6 ECOG performance status is 0 or 1. 7 Sufficient function of main organ (born marrow, kidney, heart ) and conditions filled the following criteria.

Exclusion criteria

Exclusion criteria: 1 Previous operation or RFA or PEIT within 1 year. 2 Extrahepatic metastasis or lymph nodes metastasis. 3 Active cancer of the other organs. 4 Active double cancers. 5 Concurrent infections(without hepatitis virus). 6 Medical history of severe hypersensitivity. 7 Pregnant, lacting women or women with suspected pregnancy. 8 Inappropriate patients for this study judged by physicians.

Design outcomes

Primary

Measure	Time frame
complication	—

Secondary

Measure	Time frame
response evaluation overall survival	—

Countries

Japan

Contacts

Public ContactYohei Kooka

Yame General Hospital Department of Hepatology

ymhp0389@yamehp.jp0943-23-4131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026